Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 2/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30566676 | 1.00 | MAPK1 (0.54) | MAPK1HTTRAB9AP2RX1GRM5 | |
| SCHEMBL21630009 | 0.83 | MEN1 (0.48) | MAPK1HTTRAB9AP2RX1HDAC8 | |
| SCHEMBL20766814 | 0.80 | HDAC1 (0.53) | RAB9AHDAC8ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL18160487 | 0.79 | RAB9A (0.56) | MAPK1HTTRAB9AP2RX1GRM5 | |
| SCHEMBL3441208 | 0.79 | MAPK1 (0.56) | MAPK1HTTRAB9AP2RX1GRM5 | |
| SCHEMBL18160382 | 0.79 | F10 (0.62) | MAPK1HTTRAB9AP2RX1GRM5 | |
| SCHEMBL2560439 | 0.79 | FADS1 (0.58) | HTTRAB9AHDAC8LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL18146958 | 0.78 | RAB9A (0.55) | MAPK1HTTRAB9AP2RX1GRM5 | |
| SCHEMBL21021112 | 0.77 | RAB9A (0.54) | MAPK1HTTRAB9AP2RX1GRM5 | |
| SCHEMBL2571879 | 0.75 | MITF (0.62) | MAPK1HTTRAB9AP2RX1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384283-B | Therapeutic heterocyclic compounds | 吉利德科学公司 | 2023-08-15 | — | — | CN | disclosed |
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11186579-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11040033-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3817818-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112384283-A | Therapeutic heterocyclic compounds | 吉利德科学公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3672970-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | Gilead Sciences, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| CN-111051305-A | Therapeutic heterocyclic compounds | 吉利德科学公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20200031834-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019040102-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229638-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | MAPK1 4466/4885HTT 1407/4885RAB9A 1403/4885 |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | MAPK1 4466/4885HTT 1407/4885RAB9A 1403/4885 |
| US-11040033-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | MAPK1 4466/4885HTT 1407/4885RAB9A 1403/4885 |
| US-11186579-B2 | Therapeutic heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MAPT, SLC10A1 | MAPK1 3295/4885HTT 59/4885RAB9A 879/4885 |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | SDHA, CYP11B2, ABCB1 | MAPK1 4466/4885HTT 1407/4885RAB9A 1403/4885 |
| US-20200031834-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MAPT, SLC10A1 | MAPK1 3295/4885HTT 59/4885RAB9A 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.